Today GSK, one of our members, signed up to the AllTrials campaign. The ABPI has long been an advocate of greater transparency in clinical trial data balanced with the need to ensure that disclosure policies protect patients’ personal data, companies’ intellectual property rights and confidential commercial information.
We have been actively involved in progressing this issue with all stakeholders. The AllTrials campaign is one of a number of initiatives addressing the transparency issue. Others include the EMA work streams, the Science and Technology Committee Inquiry and changes to the ABPI Code of Practice in 2012. The decision to sign up to the Alltrials campaign is one for individual companies to make.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.